Quarterly report pursuant to Section 13 or 15(d)

Discontinuing Operations - Summarized results of consolidated discontinued operations (Details)

v3.20.2
Discontinuing Operations - Summarized results of consolidated discontinued operations (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Income Statement Information          
Revenue $ 0 $ 4,621 $ 0 $ 9,638  
Cost of revenues 0 3,465 0 7,100  
Gross profit 0 1,156 0 2,538  
Research and development 0 436 0 890  
General and administrative (31) 1,983 (31) 3,510  
Sales and marketing 0 590 0 1,513  
Transaction costs 0 402 0 651  
Total operating expenses (31) 3,411 (31) 6,564  
Income (loss) from discontinuing operations 31 (2,255) 31 (4,026)  
Interest expense 0 (1,063) 0 (2,173)  
Other 35 0 43 0  
Total other income (expense) 35 (1,063) 43 (2,173)  
Net income (loss) from discontinuing operations 66 (3,318) 74 (6,199)  
Current assets of discontinuing operations:          
Accounts receivable, net of allowance for doubtful accounts of $4,518 in 2020; $4,536 in 2019 0   0   $ 71
Current assets of discontinuing operations 0   0   71
Current liabilities of discontinuing operations          
Accounts payable and accrued expenses 611   611   1,137
Due to Interpace Biosciences, Inc. 0   0   92
Current liabilities of discontinuing operations 611   611   1,229
Allowance for doubtful accounts 4,518   4,518   $ 4,536
Cash Flow Information          
Income (loss) from discontinuing operations $ 66 $ (3,318) 74 (6,199)  
Adjustments to reconcile income (loss) from discontinuing operations to net cash used in operating activities, discontinuing operations          
Depreciation     0 496  
Amortization     0 11  
Provision for bad debts     (42) 25  
Accounts payable settlements     (43) 0  
Stock-based compensation     (8) 74  
Amortization of operating lease right-of-use assets     0 345  
Amortization of discount of debt and debt issuance costs     0 602  
Loss on extinguishment of debt     0 328  
Interest added to Convertible Note     0 343  
Change in working capital components:          
Accounts receivable     113 86  
Other current assets     0 166  
Other non-current assets     0 (55)  
Accounts payable, accrued expenses and deferred revenue     (483) (680)  
Obligations under operating leases     0 (369)  
Due to Interpace Biosciences, Inc.     (92) 0  
Net cash used in operating activities, discontinuing operations     $ (481) $ (4,827)